NASDAQ:MRSNMersana Therapeutics Stock Price, Forecast & News

$21.28

+1.59 (+8.07 %)

(As of 05/29/2020 09:40 AM ET)

Add

Compare

Today's Range

$20.42

Now: $21.29▼

$22.10

50-Day Range

$7.74

MA: $9.51▼

$18.19

52-Week Range

$1.32

Now: $21.29▼

$20.75

Volume668,979 shs

Average Volume2.65 million shs

Market Capitalization$1.25 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.19

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

1.5 Analyst's Opinion

Consensus Rating
Mersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.25, Mersana Therapeutics has a potential upside of 2.8% from its current price of $19.69.
Amount of Analyst Coverage
Mersana Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Mersana Therapeutics has received 216 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mersana Therapeutics has received 185 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mersana Therapeutics has received 53.87% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote “Outperform” if you believe MRSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mersana Therapeutics does not currently pay a dividend.
Dividend Growth
Mersana Therapeutics does not have a long track record of dividend growth.

5.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mersana Therapeutics insiders have bought 18,178.01% more of their company's stock than they have sold. Specifically, they have bought $32,492,640.00 in company stock and sold $177,769.00 in company stock.
Percentage Held by Insiders
39.70% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.28% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Mersana Therapeutics are expected to grow in the coming year, from ($1.27) to ($1.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mersana Therapeutics is -14.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mersana Therapeutics is -14.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mersana Therapeutics has a P/B Ratio of 18.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.97 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MRSN

Previous Symbol

CUSIPN/A

CIK1442836

Webwww.mersana.com

Phone617-498-0020

Debt

Debt-to-Equity Ratio0.24

Current Ratio4.59

Quick Ratio4.59

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$42.12 million

Price / Sales29.79

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.07 per share

Price / Book19.89

Profitability

EPS (Most Recent Fiscal Year)($0.65)

Net Income$-28,210,000.00

Net Margins-6,099.64%

Return on Equity-78.18%

Return on Assets-57.74%

Miscellaneous

Employees86

Outstanding Shares58,950,000

Market Cap$1.25 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

How has Mersana Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN shares have increased by 204.8% and is now trading at $19.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mersana Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mersana Therapeutics.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Mersana Therapeutics.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc (NASDAQ:MRSN) announced its quarterly earnings data on Friday, May, 8th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.03. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.37 million. Mersana Therapeutics had a negative net margin of 6,099.64% and a negative return on equity of 78.18%. View Mersana Therapeutics' earnings history.

What price target have analysts set for MRSN?

5 brokerages have issued 1-year price targets for Mersana Therapeutics' shares. Their forecasts range from $14.00 to $26.00. On average, they anticipate Mersana Therapeutics' share price to reach $20.25 in the next year. This suggests a possible upside of 2.8% from the stock's current price. View analysts' price targets for Mersana Therapeutics.

Has Mersana Therapeutics been receiving favorable news coverage?

Headlines about MRSN stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the near term. View the latest news aboutMersana Therapeutics.

Who are some of Mersana Therapeutics' key competitors?

Some companies that are related to Mersana Therapeutics include BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Allakos (ALLK), Biohaven Pharmaceutical (BHVN), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), FibroGen (FGEN) and Deciphera Pharmaceuticals (DCPH). View all competitors.

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Amarin (AMRN), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Marinus Pharmaceuticals (MRNS), ImmunoGen (IMGN), vTv Therapeutics (VTVT), Advanced Micro Devices (AMD) and Clovis Oncology (CLVS).

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:

Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
Mr. David A. Spellman, Chief Financial Officer (Age 42)
Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
Mr. Mikhail Papisov Ph.D., Co-Founder
Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.58%), VR Adviser LLC (4.45%), Ghost Tree Capital LLC (3.39%), Orbimed Advisors LLC (2.28%), State Street Corp (1.18%) and JPMorgan Chase & Co. (0.76%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Enterprise Associates 14 New, Scott D Sandell and Timothy B Lowinger. View institutional ownership trends for Mersana Therapeutics.

Which major investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, JPMorgan Chase & Co., Morgan Stanley, UBS Group AG, Legal & General Group Plc, and American International Group Inc.. View insider buying and selling activity for Mersana Therapeutics.

Which major investors are buying Mersana Therapeutics stock?

MRSN stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, Ghost Tree Capital LLC, BlackRock Inc., AXA, DAFNA Capital Management LLC, Sofinnova Investments Inc., Bailard Inc., and Mackenzie Financial Corp. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Enterprise Associates 14 New. View insider buying and selling activity for Mersana Therapeutics.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $19.69.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $1.16 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff